Avadel Pharmaceuticals to Provide a Company Update and Report Fourth Quarter and Full Year 2020 Financial Results, on March 9th

Rhea-AI Summary

Avadel Pharmaceuticals (Nasdaq: AVDL) will host a conference call on March 9, 2021, at 8:30 a.m. ET to discuss its financial results for Q4 and FY 2020. The company focuses on developing FT218, a once-nightly formulation of sodium oxybate for treating narcolepsy. Investors can access the call at (877) 407-9716 for the U.S. and Canada or (201) 493-6779 internationally, with conference ID 13716363. A live audio webcast will be available on the company’s website, accessible for replay for 90 days post-event.

Positive

• Company is developing FT218, a novel treatment for narcolepsy.
• Scheduled conference call may indicate transparency and investor engagement.

Negative

• No recent financial metrics disclosed, which may raise concerns about transparency.

DUBLIN, Ireland, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Tuesday, March 9, 2021, to provide a company update and discuss the Company's financial results for the fourth quarter and full year ended December 31, 2020.

To access the conference call, investors are invited to dial (877) 407-9716 (U.S. and Canada) or (201) 493-6779 (International). The conference ID number is 13716363. A live audio webcast can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event.

Contacts:

Investor Contacts
Tom McHugh
Chief Financial Officer
Phone: (636) 449-1843
Email: tmchugh@avadel.com

Tim McCarthy
LifeSci Advisors, LLC
Phone: (212) 915.2564
Email: tim@lifesciadvisors.com

Media Contact
Patrick Bursey
LifeSci Communications, LLC
Phone: (646) 970-4688
Email: pbursey@lifescicomms.com

FAQ

What is Avadel Pharmaceuticals announcing on March 9, 2021?

Avadel Pharmaceuticals is hosting a conference call to discuss its Q4 and full year 2020 financial results.

What is FT218 developed by Avadel Pharmaceuticals?

FT218 is an investigational, once-nightly formulation of sodium oxybate aimed at treating narcolepsy.

How can I access the Avadel Pharmaceuticals conference call?

Investors can join the conference call by dialing (877) 407-9716 for U.S. and Canada or (201) 493-6779 internationally, using conference ID 13716363.

Where can I find the replay of the Avadel Pharmaceuticals conference call?

The replay of the conference call will be available on Avadel’s investor relations website for 90 days after the event.